What You Should Know: – NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35… Read More »NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M
Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more… Read More »Why Cancer Registries are Part of America’s Fight for Racial Equality
What You Should Know: – Syapse raises 68M in equity investment led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence through Syapse’s Learning Health Network. – The Syapse Learning Health Network is a global precision oncology data sharing network,… Read More »Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network
Host response can be identified by proteomic profiling, which involves analyzing a broad range of select proteins in a series of patient blood samples, with the first collected prior to treatment and the next collected after the first dose of treatment
Founded in 2020, Scorpion is agnostic about the potential therapies and targets it will explore with what it describes as its drug-hunting engine. But the company is hoping to unveil its first drug candidate this year.
What You Should Know: – Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six… Read More »Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies
What You Should Know: – CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. – CancerIQ’s technology enables hospitals to use genomics to… Read More »CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform